Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Nashville, Tennessee

This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10880
Shown on this page
12
Current sort
Recently updated
Location scope
Nashville, TN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Nashville, Tennessee. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 685–696 of 10,880 matching trials in Nashville, TN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Nashville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 1 Interventional

A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

NCT07849231
View directory record Official record
Conditions
Myeloproliferative Neoplasms (MPNs)
Interventions
DMR-001, Ruxolitinib
Drug
Lead sponsor
Damora Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT06979453
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST
Recruiting Phase 2 Interventional

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

NCT06317662
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 365 Days
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
116
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST
Active, not recruiting No phase listed Observational

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

NCT06779773
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
Avacincaptad pegol (ACP)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
Not listed
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST
Recruiting Phase 2 Interventional

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

NCT07752979
View directory record Official record
Conditions
Obesity, Overweight
Interventions
ABBV-295, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
60
States / cities
Pelham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST
Recruiting Phase 2 Interventional

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT06124157
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine
Procedure · Biological · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
366 Days to 46 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
145
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST
Recruiting Phase 1 Interventional

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

NCT05916313
View directory record Official record
Conditions
Glioma
Interventions
BI 764532
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Orange, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST
Recruiting Phase 3 Interventional

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141
View directory record Official record
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
115
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST
Recruiting Phase 3 Interventional

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242
View directory record Official record
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST
Recruiting Phase 3 Interventional

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

NCT07441681
View directory record Official record
Conditions
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cetuximab, Computed Tomography, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Survey Administration
Procedure · Drug · Biological + 2 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
150
States / cities
Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST
Recruiting Phase 2 Interventional

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06995677
View directory record Official record
Conditions
Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene Fusions
Interventions
TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
36
States / cities
Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST
Completed Phase 2 Interventional Results available

Tocilizumab in Cardiac Transplantation

NCT03644667
View directory record Official record
Conditions
Heart Transplant
Interventions
tocilizumab, Placebo, Standard of Care Triple IS
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Beverly Hills, California • La Jolla, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 15, 2026, 10:03 AM EST